Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

被引：0

作者：

Massimo Gentile

Fortunato Morabito

Giovanni Del Poeta

Francesca Romana Mauro

Gianluigi Reda

Paolo Sportoletti

Luca Laurenti

Marta Coscia

Yair Herishanu

Anna Grazia Recchia

Marzia Varettoni

Roberta Murru

Annalisa Chiarenza

Adalgisa Condoluci

Riccardo Moia

Daniela Pietrasanta

Giacomo Loseto

Ugo Consoli

Ilaria Scortechini

Francesca Maria Rossi

Antonella Zucchetto

Vincenzo Fraticelli

Ernesto Vigna

Cirino Botta

Giovanni Tripepi

Graziella D’ Arrigo

Angela Rago

Ilaria Angeletti

Annalisa Biagi

Ilaria Del Giudice

Riccardo Bomben

Gian Matteo Rigolin

Davide Rossi

Francesco Di Raimondo

Gianluca Gaidano

Aaron Polliack

Antonio Cuneo

Robin Foà

Valter Gattei

机构：

[1] Hematology Unit AO of Cosenza,Biothecnology Research Unit

[2] AO of Cosenza,Hematology Oncology Department

[3] Augusta Victoria Hospital,Division of Hematology

[4] S. Eugenio Hospital and University of Tor Vergata,Division of Hematology, Department of Translational and Precision Medicine

[5] ‘Sapienza’ University,Division of Ematologia

[6] Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano,Centro di Ricerca Emato

[7] University of Perugia,Oncologica (CREO)

[8] Fondazione Universitaria Policlinico A Gemelli di Roma,Division of Hematology

[9] A.O.U. Città della Salute e della Scienza di Torino,Sourasky Medical Center, Institute of Hematology, and Sackler Faculty of Medicine

[10] Tel-Aviv University,Division of Haematology

[11] Fondazione IRCCS Policlinico San Matteo,Hematology and Stem Cell Transplantation Unit

[12] Ospedale A. Businco,Division of Hematology, Policlinico, Department of Surgery and Medical Specialties

[13] University of Catania,Division of Hematology

[14] Oncology Institute of Southern Switzerland,Division of Hematology, Department of Translational Medicine

[15] University of Eastern Piedmont,Division of Hematology

[16] Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo,Hematology and Cell Therapy Unit

[17] IRCCS-Istituto Tumori ‘Giovanni Paolo II’,Department of Hematology

[18] G. Garibaldi Hospital,Clinical and Experimental Onco

[19] Clinica di Ematologia Ospedali Riuniti,Hematology Unit

[20] Centro di Riferimento Oncologico di Aviano (CRO) IRCCS,Hematology Section, Department of Medical Sciences

[21] CNR-IFC,Department of Hematology

[22] Research Unit of Reggio Calabria,undefined

[23] UOSD Ematologia ASL Roma 1,undefined

[24] Reparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni,undefined

[25] University of Ferrara,undefined

[26] Hadassah-Hebrew University Medical Center,undefined

来源：

Leukemia | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：235 / 238

页数：3

共 50 条

[31] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Van Den Neste, Eric
Cazin, Bruno
Janssens, Ann
Gonzalez-Barca, Eva
Jose Terol, Maria
Levy, Vincent
Perez de Oteyza, Jaime
Zachee, Pierre
Saunders, Andrew
de Frias, Merce
Campas, Clara
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
[32] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Eric Van Den Neste
Bruno Cazin
Ann Janssens
Eva González-Barca
María José Terol
Vincent Levy
Jaime Pérez de Oteyza
Pierre Zachee
Andrew Saunders
Mercè de Frias
Clara Campàs
Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
[33] Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson, Lotta
Winqvist, Maria
Asklid, Anna
Andersson, P-O
Karlsson, Karin
Karlsson, Claes
Lauri, Birgitta
Lundin, Jeanette
Mattsson, Mattias
Norin, Stefan
Sandstedt, Anna
Osterborg, Anders
BLOOD, 2015, 126 (23)
[34] Ublituximab and ibrutinib: an ingenious combination in relapsed or refractory high-risk chronic lymphocytic leukemia?
Cailly, Laura
Tomowiak, Cecile
HEMATOLOGIE, 2022, 28 (01): : 8 - 10
[35] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Riccardo Bomben
Francesca Maria Rossi
Filippo Vit
Tamara Bittolo
Antonella Zucchetto
Robel Papotti
Erika Tissino
Federico Pozzo
Massimo Degan
Jerry Polesel
Pietro Bulian
Roberto Marasca
Gianluigi Reda
Luca Laurenti
Jacopo Olivieri
Annalisa Chiarenza
Roberta Laureana
Massimiliano Postorino
Maria Ilaria Del Principe
Antonio Cuneo
Massimo Gentile
Fortunato Morabito
Gilberto Fronza
Agostino Tafuri
Francesco Zaja
Robin Foà
Francesco Di Raimondo
Giovanni Del Poeta
Valter Gattei
Leukemia, 2023, 37 : 914 - 918
[36] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Bomben, Riccardo
Rossi, Francesca Maria
Vit, Filippo
Bittolo, Tamara
Zucchetto, Antonella
Papotti, Robel
Tissino, Erika
Pozzo, Federico
Degan, Massimo
Polesel, Jerry
Bulian, Pietro
Marasca, Roberto
Reda, Gianluigi
Laurenti, Luca
Olivieri, Jacopo
Chiarenza, Annalisa
Laureana, Roberta
Postorino, Massimiliano
Del Principe, Maria Ilaria
Cuneo, Antonio
Gentile, Massimo
Morabito, Fortunato
Fronza, Gilberto
Tafuri, Agostino
Zaja, Francesco
Foa, Robin
Di Raimondo, Francesco
Del Poeta, Giovanni
Gattei, Valter
LEUKEMIA, 2023, 37 (04) : 914 - 918
[37] TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel in Combination With Ibrutinib for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 19
[38] Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Palma, Marzia
Krstic, Aleksandra
Berglof, Anna
Wang, Qing
Blomberg, Emelie
Meinke, Stephan
Kamali-Moghaddam, Masood
Shen, Qiujin
Jaremko, Georg
Lundin, Jeanette
Kimby, Eva
Hoglund, Petter
Mansson, Robert
Osterborg, Anders
Smith, Edvard
BLOOD, 2016, 128 (22)
[39] Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies
Mohammad Amin Karimi
Hanieh Norooziseyedhosseini
Reza Khademi
Alireza Ghajary
Haniyeh Kargar
Seyyedeh Sana Abdollahi
Mohaddeseh Belbasi
Mahdyieh Naziri
Niloofar Deravi
Sajjad Hajihosseini
Saharnaz Mofidi
BMC Pharmacology and Toxicology, 26 (1)
[40] Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Solman, Isabelle G.
Taylor, Marlene
You, Hana
O'Brien, Susan M.
Mulligan, Stephen P.
Byrd, John C.
Dean, James P.
James, Danelle F.
Mongan, Ann
BLOOD, 2018, 132

← 1 2 3 4 5 →